Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 42nd Annual Meeting of the European Society for Blood and Marrow Transplatation will bring together leaders in the field to discuss cellular immunotherapies including CARTs, the most recent clinical results from haploidentical transplants and the newest biological advances in stem cell transplantation. The program includes:

  • 32nd Meeting of the Nurses Group
  • 15th Meeting of the Data Management Group
  • 8th Meeting of the Quality Management Group
  • 5th Cell Therapy Day
  • 5th Paediatric Day
  • 10th Patient, Family and Donor Day (2 April, 2016)

EBMT 2016

03–06 April 2016 | Feria Valencia, Valencia, Spain

EBMT 2016

03–06 April 2016 | Feria Valencia, Valencia, Spain

The 42nd Annual Meeting of the European Society for Blood and Marrow Transplatation will bring together leaders in the field to discuss cellular immunotherapies including CARTs, the most recent clinical results from haploidentical transplants and the newest biological advances in stem cell transplantation. The program includes:

  • 32nd Meeting of the Nurses Group
  • 15th Meeting of the Data Management Group
  • 8th Meeting of the Quality Management Group
  • 5th Cell Therapy Day
  • 5th Paediatric Day
  • 10th Patient, Family and Donor Day (2 April, 2016)
Why children should be offered choices in their treatment plans 1:47
Why children should be offered choices in their treatment plans
Imelda Coyne • 3 Apr 2016
Information is key: why patients need to be empowered to learn about their disease 3:11
Information is key: why patients need to be empowered to learn about their disease
John Murray • 4 Apr 2016
The role of proteasome inhibitors in multiple myeloma 2:52
The role of proteasome inhibitors in multiple myeloma
Mohamad Mohty • 4 Apr 2016
Why it is important to involve children and adolescents in treatment decision-making 1:41
Why it is important to involve children and adolescents in treatment decision-making
Imelda Coyne • 3 Apr 2016
The significance of FLT3 mutations in AML 1:39
The significance of FLT3 mutations in AML
Ali Bazarbachi • 4 Apr 2016
Virus-specific T cells – effectiveness, safety profile and use 2:48
Virus-specific T cells – effectiveness, safety profile and use
Ann Leen • 4 Apr 2016
Drugs vs transplants in acute leukemias 1:49
Drugs vs transplants in acute leukemias
Arnon Nagler • 4 Apr 2016
Next steps for novel treatments in multiple myeloma 1:34
Next steps for novel treatments in multiple myeloma
Bruno Paiva • 4 Apr 2016
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia 2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini • 4 Apr 2016
FLT3 inhibitors – their role in AML 2:30
FLT3 inhibitors – their role in AML
Ali Bazarbachi • 4 Apr 2016
Highlights from EBMT 2016: Immunotherapy 2:27
Highlights from EBMT 2016: Immunotherapy
Arnon Nagler • 4 Apr 2016
Assessment of response in multiple myeloma: next steps 2:15
Assessment of response in multiple myeloma: next steps
Bruno Paiva • 4 Apr 2016
Safety issues with CAR T-cell therapy for acute lymphocytic leukemia 2:19
Safety issues with CAR T-cell therapy for acute lymphocytic leukemia
Catherine Bollard • 4 Apr 2016
Role of nurses in fungal disease management 1:12
Role of nurses in fungal disease management
Antonio Pagliuca • 4 Apr 2016
What has changed in AML treatment in the last 30 years? 1:45
What has changed in AML treatment in the last 30 years?
Antonio Pagliuca • 4 Apr 2016
The future of treating acute leukemias 1:19
The future of treating acute leukemias
Giovanni Martinelli • 4 Apr 2016
The content of VJHemOnc is intended for healthcare professionals